Uvéites et biothérapies
Tóm tắt
Từ khóa
Tài liệu tham khảo
Jabs, 2000, Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel, Am J Ophthalmol, 130, 492, 10.1016/S0002-9394(00)00659-0
Heiligenhaus, 2010, Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease, Graefes Arch Clin Exp Ophthalmol, 248, 1531, 10.1007/s00417-010-1485-8
Zeghidi, 2014, [Ocular manifestations in Behçet's disease], Rev Med Interne, 35, 97, 10.1016/j.revmed.2013.10.011
Pruna, 2012, [Uveitis as a presenting manifestation of sarcoidosis: clinical characteritics of a series of 23 cases], Rev Med Interne, 33, 615, 10.1016/j.revmed.2012.06.006
Dick, 2013, Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials, Ophthalmology, 120, 777, 10.1016/j.ophtha.2012.09.040
Buggage, 2007, A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease, Ocul Immunol Inflamm, 15, 63, 10.1080/09273940701299370
Naïja, 2014, [Interferon dysoric retinopathy in chronic hepatitis C. A case report and literature review], Rev Med Interne, 35, 543, 10.1016/j.revmed.2013.10.005
Alpsoy, 2002, Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study, Arch Dermatol, 138, 467, 10.1001/archderm.138.4.467
Hazirolan, 2013, Light on the horizont: biologicals in Behçet uveitis, Acta Ophthalmol (Copenh), 91, 297, 10.1111/j.1755-3768.2011.02348.x
Deuter, 2012, Interferon-α therapy in noninfectious uveitis, Dev Ophthalmol, 51, 90, 10.1159/000336324
Hatemi, 2009, Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease, Ann Rheum Dis, 68, 1528, 10.1136/ard.2008.087957
Deuter, 2006, Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study, Retina, 26, 786, 10.1097/01.iae.0000244265.75771.71
Butler, 2012, Interferon alpha 2b in the treatment of uveitic cystoid macular edema, Ocul Immunol Inflamm, 20, 86, 10.3109/09273948.2011.645989
Bodaghi, 2007, Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients, Br J Ophthalmol, 91, 335, 10.1136/bjo.2006.101550
Plskova, 2007, Interferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitis, Am J Ophthalmol, 144, 55, 10.1016/j.ajo.2007.03.050
Becker, 2005, Interferon as a treatment for uveitis associated with multiple sclerosis, Br J Ophthalmol, 89, 1254, 10.1136/bjo.2004.061119
Darnige, 2014, [Treatments with immunoglobulin and thrombotic adverse events], Rev Med Interne, 35, 39, 10.1016/j.revmed.2013.07.006
Cassoux, 2002, Efficacité et tolérance des immunoglobulines intraveineuses dans le traitement de la rétinochoroïdopathie de type Birdshot, J Fr Ophtalmol, 25, 23
Rosenbaum, 1999, The treatment of refractory uveitis with intravenous immunoglobulin, Am J Ophthalmol, 127, 545, 10.1016/S0002-9394(99)00029-X
Tellier, 2007, Human immunoglobulins in intraocular inflammation, Ann N Y Acad Sci, 1110, 337, 10.1196/annals.1423.036
Rodrigues, 2009, Therapeutic monoclonal antibodies in ophthalmology, Prog Retin Eye Res, 28, 117, 10.1016/j.preteyeres.2008.11.005
Sfikakis, 2001, Effect of infliximab on sight-threatening panuveitis in Behçet's disease, Lancet, 358, 295, 10.1016/S0140-6736(01)05497-6
Markomichelakis, 2004, Infliximab for chronic cystoid macular edema associated with uveitis, Am J Ophthalmol, 138, 648, 10.1016/j.ajo.2004.04.066
Giansanti, 2004, Infliximab for the treatment of posterior uveitis with retinal neovascularization in Behçet disease, Eur J Ophthalmol, 14, 445, 10.1177/112067210401400515
Arida, 2011, Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients, Semin Arthritis Rheum, 41, 61, 10.1016/j.semarthrit.2010.09.002
Sfikakis, 2007, Anti-TNF therapy in the management of Behcet's disease: review and basis for recommendations, Rheumatol Oxf Engl, 46, 736, 10.1093/rheumatology/kem034
Hatemi, 2008, EULAR recommendations for the management of Behçet disease, Ann Rheum Dis, 67, 1656, 10.1136/ard.2007.080432
Markomichelakis, 2011, A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet's disease: a comparative 4-week study, Rheumatol Oxf Engl, 50, 593, 10.1093/rheumatology/keq366
Diaz-Llopis, 2008, Adalimumab therapy for refractory uveitis: a pilot study, J Ocul Pharmacol Ther, 24, 351, 10.1089/jop.2007.0104
Suhler, 2013, Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial, Br J Ophthalmol, 97, 481, 10.1136/bjophthalmol-2012-302292
Dobner, 2013, A three-centre experience with adalimumab for the treatment of non-infectious uveitis, Br J Ophthalmol, 97, 134, 10.1136/bjophthalmol-2011-301401
Simonini, 2011, Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab, Arthritis Care Res, 63, 612, 10.1002/acr.20404
Zannin, 2013, Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year follow-up data from the Italian Registry, J Rheumatol, 40, 74, 10.3899/jrheum.120583
Anink, 2013, Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children Register, Rheumatol Oxf Engl, 52, 712, 10.1093/rheumatology/kes373
Artornsombudh, 2013, Infliximab treatment of patients with birdshot retinochoroidopathy, Ophthalmology, 120, 588, 10.1016/j.ophtha.2012.05.048
Varron, 2011, Uvéites sarcoïdosiques : actualités diagnostiques et thérapeutiques, Rev Med Interne, 32, 86, 10.1016/j.revmed.2010.09.003
Maneiro, 2012, Efficacy and safety of TNF antagonists in sarcoidosis: data from the Spanish registry of biologics BIOBADASER and a systematic review, Semin Arthritis Rheum, 42, 89, 10.1016/j.semarthrit.2011.12.006
Judson, 2008, Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial, Eur Respir J, 31, 1189, 10.1183/09031936.00051907
Erckens, 2012, Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis, Graefes Arch Clin Exp Ophthalmol, 250, 713, 10.1007/s00417-011-1844-0
Saadoun, 2013, Biotherapies in inflammatory ocular disorders: interferons, immunoglobulins, monoclonal antibodies, Autoimmun Rev, 12, 774, 10.1016/j.autrev.2013.02.002
Sturfelt, 2007, Neurosarcoidosis in a patient with rheumatoid arthritis during treatment with infliximab, J Rheumatol, 34, 2313
Hashkes, 2003, Sarcoid-related uveitis occurring during etanercept therapy, Clin Exp Rheumatol, 21, 645
Braun, 2005, Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept, Arthritis Rheum, 52, 2447, 10.1002/art.21197
Guignard, 2006, Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study, Ann Rheum Dis, 65, 1631, 10.1136/ard.2006.052092
Zochling, 2006, ASAS/EULAR recommendations for the management of ankylosing spondylitis, Ann Rheum Dis, 65, 442, 10.1136/ard.2005.041137
Mesquida, 2013, Behçet disease-associated uveitis successfully treated with golimumab, Ocul Immunol Inflamm, 21, 160, 10.3109/09273948.2012.741744
Gaujoux-Viala, 2012, Scleritis: a paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease, J Rheumatol, 39, 233, 10.3899/jrheum.110865
Lim, 2007, Do tumor necrosis factor inhibitors cause uveitis?. A registry-based study, Arthritis Rheum, 56, 3248, 10.1002/art.22918
Lefebvre, 2007, L’uvée et le cristallin : toxicité des nouveaux médicament, Bull Soc Belge Ophtalmol, 304, 133
Takase, 2011, Successful switching to adalimumab in an infliximab-allergic patient with severe Behçet disease-related uveitis, Rheumatol Int, 31, 243, 10.1007/s00296-009-1178-y
Kempen, 2009, Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study, BMJ, 339, b2480, 10.1136/bmj.b2480
Levy-Clarke, 2014, Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders, Ophthalmology, 121, 785, 10.1016/j.ophtha.2013.09.048
Specks, 2013, Efficacy of remission-induction regimens for ANCA-associated vasculitis, N Engl J Med, 369, 417, 10.1056/NEJMoa1213277
Molloy, 2012, Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies, Arthritis Rheum, 64, 3043, 10.1002/art.34468
Heiligenhaus, 2011, Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab), Rheumatol Oxf Engl, 50, 1390, 10.1093/rheumatology/ker107
Davatchi, 2010, Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study), Int J Rheum Dis, 13, 246, 10.1111/j.1756-185X.2010.01546.x
Miserocchi, 2011, Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases, Autoimmun Rev, 11, 35, 10.1016/j.autrev.2011.07.001
Sedyshev, 2013, [IgG4-related disease: patient group characterization and rituximab therapy], Ter Arkhiv, 85, 48
Seo, 2008, Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations, J Rheumatol, 35, 2017
Aries, 2006, Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations, Ann Rheum Dis, 65, 853, 10.1136/ard.2005.044420
Taylor, 2009, Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis, Arthritis Rheum, 60, 1540, 10.1002/art.24454
Charles, 2013, Rituximab: recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides, Presse Med, 42, 1317, 10.1016/j.lpm.2013.08.003
Gül, 2012, Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study, Ann Rheum Dis, 71, 563, 10.1136/annrheumdis-2011-155143
Simonini, 2013, Clinical and transcriptional response to the long-acting interleukin-1 blocker canakinumab in Blau syndrome-related uveitis, Arthritis Rheum, 65, 513, 10.1002/art.37776
Yoshimura, 2009, Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis, Rheumatol Oxf Engl, 48, 347, 10.1093/rheumatology/ken489
Haruta, 2011, Blockade of interleukin-6 signaling suppresses not only Th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis, Invest Ophthalmol Vis Sci, 52, 3264, 10.1167/iovs.10-6272
Kaly, 2012, Tocilizumab: a novel therapy for non-organ-specific autoimmune diseases, Best Pract Res Clin Rheumatol, 26, 157, 10.1016/j.berh.2012.01.001
Muselier, 2011, Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis, Ocul Immunol Inflamm, 19, 382, 10.3109/09273948.2011.606593
Hirano, 2012, A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab, Mod Rheumatol Jpn Rheum Assoc, 22, 298, 10.3109/s10165-011-0497-5
Oshitari, 2012, Refractory uveitis in patient with castleman disease successfully treated with tocilizumab, Case Rep Ophthalmol Med, 2012, 968180
Tappeiner, 2012, Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis?, J Rheumatol, 39, 1294, 10.3899/jrheum.120010
Adán, 2013, Tocilizumab treatment for refractory uveitis-related cystoid macular edema, Graefes Arch Clin Exp Ophthalmol, 251, 2627, 10.1007/s00417-013-2436-y
Kötter, 2003, Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis, Br J Ophthalmol, 87, 423, 10.1136/bjo.87.4.423
Tugal-Tutkun, 2006, Results of interferon-alfa therapy in patients with Behçet uveitis, Graefes Arch Clin Exp Ophthalmol, 244, 1692, 10.1007/s00417-006-0346-y
Gueudry, 2008, Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease, Am J Ophthalmol, 146, 837, 10.1016/j.ajo.2008.08.038
Krause, 2008, Long-term visual prognosis of patients with ocular Adamantiades-Behçet's disease treated with interferon-alpha-2a, J Rheumatol, 35, 896
Sobaci, 2010, Safety and effectiveness of interferon alpha-2a in treatment of patients with Behçet's uveitis refractory to conventional treatments, Ophthalmology, 117, 1430, 10.1016/j.ophtha.2009.11.022
Deuter, 2010, Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet's disease, Arthritis Rheum, 62, 2796, 10.1002/art.27581
Onal, 2011, Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis, Arch Ophthalmol, 129, 288, 10.1001/archophthalmol.2011.3
Yalçindağ, 2012, Results of interferon alpha-2a therapy in patients with Behcet's disease, J Ocul Pharmacol Ther, 28, 439, 10.1089/jop.2011.0238
Niccoli, 2007, Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study, Rheumatol Oxf Engl, 46, 1161, 10.1093/rheumatology/kem101
Tugal-Tutkun, 2005, Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial, Arthritis Rheum, 52, 2478, 10.1002/art.21231
Tognon, 2007, Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects, Ann N Y Acad Sci, 1110, 474, 10.1196/annals.1423.050
Okada, 2012, Multicenter study of infliximab for refractory uveoretinitis in Behçet disease, Arch Ophthalmol, 130, 592, 10.1001/archophthalmol.2011.2698
Giardina, 2011, One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçet's disease refractory to standard immunosuppressive drugs, Rheumatol Int, 31, 33, 10.1007/s00296-009-1213-z
Bodaghi, 2005, Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors, Ann Rheum Dis, 64, 962, 10.1136/ard.2004.025882
Sobrin, 2007, Infliximab therapy for the treatment of refractory ocular inflammatory disease, Arch Ophthalmol, 125, 895, 10.1001/archopht.125.7.895
Lindstedt, 2005, Anti-TNF-alpha therapy for sight threatening uveitis, Br J Ophthalmol, 89, 533, 10.1136/bjo.2003.037192
Galor, 2006, Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation, Ophthalmology, 113, 2317, 10.1016/j.ophtha.2006.04.038
Suhler, 2009, Infliximab therapy for refractory uveitis: 2-year results of a prospective trial, Arch Ophthalmol, 127, 819, 10.1001/archophthalmol.2009.141